| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/03/2023 | 247.52% | B. Riley Securities | → $20 | Reiterates | Buy → Buy |
| 09/07/2023 | 768.81% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy |
| 09/06/2023 | 101.56% | HSBC | → $11.6 | Initiates Coverage On | → Buy |
| 08/15/2023 | 768.81% | HC Wainwright & Co. | $53 → $50 | Maintains | Buy |
| 05/16/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | Buy → Buy |
| 04/20/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 02/21/2023 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 02/21/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 02/07/2023 | 820.94% | HC Wainwright & Co. | → $53 | Reiterates | → Buy |
| 10/31/2022 | 212.77% | B. Riley Securities | $16 → $18 | Maintains | Buy |
| 10/31/2022 | 820.94% | HC Wainwright & Co. | $45 → $53 | Maintains | Buy |
| 09/08/2022 | 247.52% | Cantor Fitzgerald | → $20 | Initiates Coverage On | → Overweight |
| 08/25/2022 | 178.02% | B. Riley Securities | → $16 | Initiates Coverage On | → Buy |
| 08/03/2021 | 681.93% | HC Wainwright & Co. | $57 → $45 | Maintains | Buy |
| 04/01/2021 | 890.44% | HC Wainwright & Co. | $65 → $57 | Maintains | Buy |
| 06/04/2020 | -47.87% | HC Wainwright & Co. | → $3 | Initiates Coverage On | → Buy |
What is the target price for Actinium Pharma (ATNM)?
The latest price target for Actinium Pharma (AMEX: ATNM) was reported by B. Riley Securities on October 3, 2023. The analyst firm set a price target for $20.00 expecting ATNM to rise to within 12 months (a possible 247.52% upside). 11 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Actinium Pharma (ATNM)?
The latest analyst rating for Actinium Pharma (AMEX: ATNM) was provided by B. Riley Securities, and Actinium Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Actinium Pharma (ATNM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Actinium Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Actinium Pharma was filed on October 3, 2023 so you should expect the next rating to be made available sometime around October 3, 2024.
Is the Analyst Rating Actinium Pharma (ATNM) correct?
While ratings are subjective and will change, the latest Actinium Pharma (ATNM) rating was a reiterated with a price target of $0.00 to $20.00. The current price Actinium Pharma (ATNM) is trading at is $5.76, which is within the analyst's predicted range.